Leaflet FEMOSTON MINI 0.5mg / 2.5mg film-coated tablets


Indicated for: menopausal symptoms

Substance: estradiol + dydrogesterone (estrogen + progestogen)

ATC: G03FA14 (Genito urinary system and sex hormones | Progestogens and estrogens in combination | Progestogens and estrogens, fixed combinations)

The combination of estradiol and dydrogesterone is used in hormone replacement therapy (HRT) for postmenopausal women to relieve symptoms associated with estrogen deficiency, such as hot flashes, night sweats, vaginal dryness, and to prevent osteoporosis.

- Estradiol is an estrogen hormone that replaces the natural estrogen levels that decrease during postmenopause.
- Dydrogesterone is a progestogen that protects the uterine lining (endometrium) from the negative effects of estradiol, preventing endometrial hyperplasia.

This combination is taken orally, usually once daily, as directed by a doctor.

Common side effects include nausea, headache, breast tenderness, irregular vaginal bleeding, and mood changes. Rarely, more serious reactions such as thromboembolism, breast cancer, or uterine cancer may occur, requiring careful medical monitoring.

The treatment should be used as prescribed by a doctor, and the benefits and risks should be periodically assessed.

General data about FEMOSTON MINI 0.5mg / 2.5mg

  • Substance: estradiol + dydrogesterone
  • Date of last drug list: 02-10-2013
  • Commercial code: W59812001
  • Concentration: 0.5mg / 2.5mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 14
  • Product type: original
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Concentrations available for estradiol + dydrogesterone

  • 0.5mg/2.5mg
  • 1mg/10mg
  • 1mg/5mg
  • 2mg/10mg